Use of intravenous gamma globulins in neuroimmunologic diseases

Norman Latov, Vinay Chaudhry, Carol Lee Koski, Robert P. Lisak, Brian R. Apatoff, Angelika F. Hahn, James F. Howard

Research output: Contribution to journalArticlepeer-review

35 Scopus citations


Intravenous gamma globulin (IVIg) is used in the treatment of immunologic diseases that affect the entire neuroaxis, including the brain, spinal cord, peripheral nerves, muscles, and neuromuscular junction. The panel reviewed the available literature on the use of IVIg in order to evaluate the efficacy of this therapy in neuroimmunologic diseases. In prospective, rigorously controlled, double-blinded clinical trials, IVIg was found to have proven efficacy in the Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, dermatomyositis, and Lambert-Eaton myasthenic syndrome. It was found to be probably effective in myasthenia gravis and polymyositis, and possibly effective in several other neuroimmunologic diseases. Further studies are needed to evaluate the use of IVIg for neuroimmunologic diseases in which its efficacy is suspected but not proven and to elucidate its mechanisms of action.

Original languageEnglish (US)
Pages (from-to)S126-S132
JournalJournal of Allergy and Clinical Immunology
Issue number4
StatePublished - 2001
Externally publishedYes


  • Chronic inflammatory demyelinating polyneuropathy
  • Guillain-Barré syndrome
  • Inflammatory neuropathy
  • Intravenous gamma globulin
  • Neuroimmunology
  • Neuropathy
  • Peripheral neuropathy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Use of intravenous gamma globulins in neuroimmunologic diseases'. Together they form a unique fingerprint.

Cite this